Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently reported its full-year 2025 financial results and outlined progress across its QTORIN drug development pipeline, including plans to submit a new …
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline Read More
MALVERN, PA — Neuronetics, Inc. (Nasdaq: STIM) reported higher fourth-quarter and full-year 2025 revenue, narrowed its losses, posted positive operating cash flow in the fourth quarter, and said Dan Reuvers …
Neuronetics Reports Higher Revenue, Narrows Loss, Sets 2026 Outlook Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) reported its 2025 financial results and said it advanced late-stage clinical development of its investigational drug buntanetap, including launching a Phase 3 …
Annovis Reports 2025 Results, Advances Buntanetap Trials Read More
WAYNE, PA — Trinseo (NYSE: TSE) reported a fourth-quarter 2025 net loss of $251 million and a full-year net loss of $546 million, driven by lower sales volumes, pricing pressure, …
Trinseo Reports 2025 Loss as Sales Decline and Restructuring Costs Rise Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported financial results for the fourth quarter and full year ended December 31, 2025, citing growth in sales of its dermatology …
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth Read More
MALVERN, PA — TELA Bio Inc. (NASDAQ: TELA) said it will report financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 24, 2026.
TELA Bio to Report Fourth Quarter and Full-Year 2025 Results March 24 Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will host a conference call and live webcast Wednesday to discuss its financial results for the fourth quarter …
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results Read More
EXTON, PA — Omega Flex, Inc. (NASDAQ: OFLX) reported net sales of $98,296,000 for 2025, down from $101,681,000 in 2024, as lower unit volumes weighed on performance.
Omega Flex Reports Lower Sales and Net Income for 2025 Read More
MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) reported fourth quarter and full-year 2025 financial results and provided updates on its clinical pipeline, including completion of enrollment for a Phase 3 …
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline Read More MALVERN, PA — Neuronetics, Inc. (Nasdaq: STIM) said it will release financial and operating results for the fourth quarter of 2025 before markets open Tuesday, March 17.
Neuronetics to Report Fourth Quarter 2025 Results March 17 Read More